Stopped: The trial was stopped because of inability to reach target sample size.
The investigators hypothesize that compared to untreated controls, erythropoietin (EPO) therapy in anemic patients with chronic kidney disease will raise diastolic blood pressure (BP). The magnitude of increase in diastolic BP at 12 weeks after treatment will be related to two factors. First, endothelial dysfunction and worsening of endothelial function from baseline to 4 weeks and second, the change of forearm blood flow in response to breathing oxygen and the change in this measure from baseline to 4 weeks. Study procedures include fasting blood draws, ambulatory blood pressure, urine collection, and forearm blood flow tests. The study hopes to accrue 160 subjects.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change in Diastolic Blood Pressure in EPO Treated Patients Compared to Delayed Start Controls
Timeframe: Baseline to 12 weeks
Within Group Change in Diastolic Blood Pressure in the Delayed Start Group
Timeframe: 12 to 24 weeks compared to baseline to 12 weeks